This medical condition has either been superseded or has become inactive
| Specific Conditions |
|
| Level of Evidence | Insufficient data (Category 4a) |
|
Intravenous immunoglobulin (IVIg) may be considered in the management or prevention of severe haemolytic transfusion reaction not responding to other interventions (e.g. corticosteroids). Refer to the current product information sheet for further information. The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient. |
|
| Bibliography |
|---|
| Win, N, Madan, B, Gale, R, et al 2005, ‘Intravenous immunoglobulin given to lymphoma patients with recurrent haemolytic transfusion reactions after transfusion of compatible blood’, Hematology, vol. 10, no. 5, pp. 375–8. |